TrialCancer2020

Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.

Lucia Masarova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.